Content matching 'autolus'
Autolus Ltd, an oncology spin-out from University College (UCL) London, has raised £30 million in a Series A financing from Syncona LLP in order to develop a new generation of engineered T cell therapies. The funding, which is significant for a start-up, reflects the expectations of the founders that the new T cell technology will revolutionise the treatment of cancer. Besides Syncona, the other founder is UCL Business Plc, the technology transfer arm of UCL.
Cell therapy weekly: Scott Gottlieb resigns from FDA and Japan to commence iPSC trial for corneal disease
The cohort of companies developing products for treating cancer with genetically engineered T-cells has increased with the announcement that Merck Serono and Intrexon Corp will collaborate to generate new drug candidates using the technology.
Cell therapy weekly: Vital Therapies abandons liver cell therapy, loses 80% share price